Polymer-coated paclitaxel-eluting stents for the treatment of stenosed native arteriovenous fistulas: Long-term results from the ELUDIA study

Background: Percutaneous transluminal angioplasty is the preferred treatment of stenosed failing arteriovenous fistulas (AVF) but is hampered by increasing rates of vascular restenosis because of development of myointimal hyperplasia. Methods: This multicenter observational study of polymer-coated l...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The journal of vascular access 2024-09, Vol.25 (5), p.1593-1600
Hauptverfasser: Katsanos, Konstantinos, Ho, Pei, Tang, Tjun Yip, Vlachou, Elina, Yap, Charyl Jia Qi, Kitrou, Panagiotis M, Karnabatidis, Dimitrios
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1600
container_issue 5
container_start_page 1593
container_title The journal of vascular access
container_volume 25
creator Katsanos, Konstantinos
Ho, Pei
Tang, Tjun Yip
Vlachou, Elina
Yap, Charyl Jia Qi
Kitrou, Panagiotis M
Karnabatidis, Dimitrios
description Background: Percutaneous transluminal angioplasty is the preferred treatment of stenosed failing arteriovenous fistulas (AVF) but is hampered by increasing rates of vascular restenosis because of development of myointimal hyperplasia. Methods: This multicenter observational study of polymer-coated low-dose paclitaxel-eluting stents (ELUvia stents by Boston Scientific) in stenosed AVF undergoing hemoDIAlysis (ELUDIA) was jointly conducted in three tertiary hospitals from Greece and Singapore. Failure of AVF was defined according to K-DOQI criteria and significant fistula stenosis (>50%DS by visual estimate) was determined with subtraction angiography. Patients were considered for ELUVIA stent insertion based on significant elastic recoil following balloon angioplasty for the treatment of a single vascular stenosis within a native AVF. The primary outcome measure was sustained long-term patency of the treated lesion/fistula circuit defined as successful stent placement with resumption of uninterrupted hemodialysis and without significant vascular restenosis (50%DS threshold) or other secondary interventions during follow-up. Results: Some 23 patients received the ELUVIA paclitaxel-eluting stent (eight radiocephalic, 12 brachiocephalic, and three transposed brachiobasilic native AVFs). Mean AVF age at the time of failure was 33.9 ± 20.4 months. Treated lesions included 12 stenoses at the juxta-anastomotic segment, nine at the outflow veins, and two cephalic arch lesions with a mean diameter stenosis of 86 ± 8%. Median stent diameter and length used were 7 mm and 40 mm, respectively. After a median follow-up period of 20 months, some 18 stents out of 23 cases remained patent (cumulative rate 78.3%) without any clinical or imaging evidence of recurrent stenosis. Estimated primary patency of the ELUVIA stents was 80.6% and of the corresponding fistula circuit 65.1% at 2 years by Kaplan-Meier methods. Conclusions: This observational study has shown promising long-term results of polymer-coated paclitaxel-eluting stents for the treatment of failing arteriovenous fistulas. Large-scale controlled studies are necessary.
doi_str_mv 10.1177/11297298231174263
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2828364340</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_11297298231174263</sage_id><sourcerecordid>2828364340</sourcerecordid><originalsourceid>FETCH-LOGICAL-c340t-110e577894013a459714039d5292021133e804bcac12812596f7e056df325d563</originalsourceid><addsrcrecordid>eNp9kctOwzAQRS0EgvL4ADbISzYBj-3ECbuqvCpVggVdRyaZlCAnLraD6Efwz7i0sEFiZXvuvWdsDyGnwC4AlLoE4IXiRc5FPEqeiR0yAsVlkjHBd-M-6snacEAOvX9ljBcpyH1yIJSQwFk-Ip-P1qw6dElldcCaLnVl2qA_0CRohtD2C-oD9sHTxjoaXpAGhzp0sURt861ZH3O9Du07Uu0Cuta-x-oQI60Pg9H-is5sv0ii1FGHfjBrnLPdN-9mNr-ejiNpqFfHZK_RxuPJdj0i89ubp8l9Mnu4m07Gs6QSkoUEgGGqVF5IBkLLtFAgmSjqlBeccQAhMGfyudIV8Bx4WmSNQpZmdSN4WqeZOCLnG-7S2bcBfSi71ldojO4xXrzkOc9FJmOzaIWNtXLWe4dNuXRtp92qBFaup1D-mULMnG3xw3OH9W_i59uj4WJj8HqB5asdXB-f-w_xC8Whj-U</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2828364340</pqid></control><display><type>article</type><title>Polymer-coated paclitaxel-eluting stents for the treatment of stenosed native arteriovenous fistulas: Long-term results from the ELUDIA study</title><source>Access via SAGE</source><source>MEDLINE</source><creator>Katsanos, Konstantinos ; Ho, Pei ; Tang, Tjun Yip ; Vlachou, Elina ; Yap, Charyl Jia Qi ; Kitrou, Panagiotis M ; Karnabatidis, Dimitrios</creator><creatorcontrib>Katsanos, Konstantinos ; Ho, Pei ; Tang, Tjun Yip ; Vlachou, Elina ; Yap, Charyl Jia Qi ; Kitrou, Panagiotis M ; Karnabatidis, Dimitrios</creatorcontrib><description>Background: Percutaneous transluminal angioplasty is the preferred treatment of stenosed failing arteriovenous fistulas (AVF) but is hampered by increasing rates of vascular restenosis because of development of myointimal hyperplasia. Methods: This multicenter observational study of polymer-coated low-dose paclitaxel-eluting stents (ELUvia stents by Boston Scientific) in stenosed AVF undergoing hemoDIAlysis (ELUDIA) was jointly conducted in three tertiary hospitals from Greece and Singapore. Failure of AVF was defined according to K-DOQI criteria and significant fistula stenosis (&gt;50%DS by visual estimate) was determined with subtraction angiography. Patients were considered for ELUVIA stent insertion based on significant elastic recoil following balloon angioplasty for the treatment of a single vascular stenosis within a native AVF. The primary outcome measure was sustained long-term patency of the treated lesion/fistula circuit defined as successful stent placement with resumption of uninterrupted hemodialysis and without significant vascular restenosis (50%DS threshold) or other secondary interventions during follow-up. Results: Some 23 patients received the ELUVIA paclitaxel-eluting stent (eight radiocephalic, 12 brachiocephalic, and three transposed brachiobasilic native AVFs). Mean AVF age at the time of failure was 33.9 ± 20.4 months. Treated lesions included 12 stenoses at the juxta-anastomotic segment, nine at the outflow veins, and two cephalic arch lesions with a mean diameter stenosis of 86 ± 8%. Median stent diameter and length used were 7 mm and 40 mm, respectively. After a median follow-up period of 20 months, some 18 stents out of 23 cases remained patent (cumulative rate 78.3%) without any clinical or imaging evidence of recurrent stenosis. Estimated primary patency of the ELUVIA stents was 80.6% and of the corresponding fistula circuit 65.1% at 2 years by Kaplan-Meier methods. Conclusions: This observational study has shown promising long-term results of polymer-coated paclitaxel-eluting stents for the treatment of failing arteriovenous fistulas. Large-scale controlled studies are necessary.</description><identifier>ISSN: 1129-7298</identifier><identifier>ISSN: 1724-6032</identifier><identifier>EISSN: 1724-6032</identifier><identifier>DOI: 10.1177/11297298231174263</identifier><identifier>PMID: 37341208</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Aged ; Angioplasty, Balloon - adverse effects ; Angioplasty, Balloon - instrumentation ; Arteriovenous Shunt, Surgical - adverse effects ; Cardiovascular Agents - administration &amp; dosage ; Coated Materials, Biocompatible ; Drug-Eluting Stents ; Female ; Graft Occlusion, Vascular - diagnostic imaging ; Graft Occlusion, Vascular - etiology ; Graft Occlusion, Vascular - physiopathology ; Graft Occlusion, Vascular - therapy ; Greece ; Humans ; Male ; Middle Aged ; Paclitaxel - administration &amp; dosage ; Prosthesis Design ; Recurrence ; Renal Dialysis ; Risk Factors ; Tertiary Care Centers ; Time Factors ; Treatment Outcome ; Upper Extremity - blood supply ; Vascular Patency</subject><ispartof>The journal of vascular access, 2024-09, Vol.25 (5), p.1593-1600</ispartof><rights>The Author(s) 2023</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c340t-110e577894013a459714039d5292021133e804bcac12812596f7e056df325d563</citedby><cites>FETCH-LOGICAL-c340t-110e577894013a459714039d5292021133e804bcac12812596f7e056df325d563</cites><orcidid>0000-0001-6312-1836 ; 0000-0003-4560-2374 ; 0000-0002-8606-0842</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/11297298231174263$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/11297298231174263$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>315,782,786,21828,27933,27934,43630,43631</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37341208$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Katsanos, Konstantinos</creatorcontrib><creatorcontrib>Ho, Pei</creatorcontrib><creatorcontrib>Tang, Tjun Yip</creatorcontrib><creatorcontrib>Vlachou, Elina</creatorcontrib><creatorcontrib>Yap, Charyl Jia Qi</creatorcontrib><creatorcontrib>Kitrou, Panagiotis M</creatorcontrib><creatorcontrib>Karnabatidis, Dimitrios</creatorcontrib><title>Polymer-coated paclitaxel-eluting stents for the treatment of stenosed native arteriovenous fistulas: Long-term results from the ELUDIA study</title><title>The journal of vascular access</title><addtitle>J Vasc Access</addtitle><description>Background: Percutaneous transluminal angioplasty is the preferred treatment of stenosed failing arteriovenous fistulas (AVF) but is hampered by increasing rates of vascular restenosis because of development of myointimal hyperplasia. Methods: This multicenter observational study of polymer-coated low-dose paclitaxel-eluting stents (ELUvia stents by Boston Scientific) in stenosed AVF undergoing hemoDIAlysis (ELUDIA) was jointly conducted in three tertiary hospitals from Greece and Singapore. Failure of AVF was defined according to K-DOQI criteria and significant fistula stenosis (&gt;50%DS by visual estimate) was determined with subtraction angiography. Patients were considered for ELUVIA stent insertion based on significant elastic recoil following balloon angioplasty for the treatment of a single vascular stenosis within a native AVF. The primary outcome measure was sustained long-term patency of the treated lesion/fistula circuit defined as successful stent placement with resumption of uninterrupted hemodialysis and without significant vascular restenosis (50%DS threshold) or other secondary interventions during follow-up. Results: Some 23 patients received the ELUVIA paclitaxel-eluting stent (eight radiocephalic, 12 brachiocephalic, and three transposed brachiobasilic native AVFs). Mean AVF age at the time of failure was 33.9 ± 20.4 months. Treated lesions included 12 stenoses at the juxta-anastomotic segment, nine at the outflow veins, and two cephalic arch lesions with a mean diameter stenosis of 86 ± 8%. Median stent diameter and length used were 7 mm and 40 mm, respectively. After a median follow-up period of 20 months, some 18 stents out of 23 cases remained patent (cumulative rate 78.3%) without any clinical or imaging evidence of recurrent stenosis. Estimated primary patency of the ELUVIA stents was 80.6% and of the corresponding fistula circuit 65.1% at 2 years by Kaplan-Meier methods. Conclusions: This observational study has shown promising long-term results of polymer-coated paclitaxel-eluting stents for the treatment of failing arteriovenous fistulas. Large-scale controlled studies are necessary.</description><subject>Aged</subject><subject>Angioplasty, Balloon - adverse effects</subject><subject>Angioplasty, Balloon - instrumentation</subject><subject>Arteriovenous Shunt, Surgical - adverse effects</subject><subject>Cardiovascular Agents - administration &amp; dosage</subject><subject>Coated Materials, Biocompatible</subject><subject>Drug-Eluting Stents</subject><subject>Female</subject><subject>Graft Occlusion, Vascular - diagnostic imaging</subject><subject>Graft Occlusion, Vascular - etiology</subject><subject>Graft Occlusion, Vascular - physiopathology</subject><subject>Graft Occlusion, Vascular - therapy</subject><subject>Greece</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Paclitaxel - administration &amp; dosage</subject><subject>Prosthesis Design</subject><subject>Recurrence</subject><subject>Renal Dialysis</subject><subject>Risk Factors</subject><subject>Tertiary Care Centers</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Upper Extremity - blood supply</subject><subject>Vascular Patency</subject><issn>1129-7298</issn><issn>1724-6032</issn><issn>1724-6032</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kctOwzAQRS0EgvL4ADbISzYBj-3ECbuqvCpVggVdRyaZlCAnLraD6Efwz7i0sEFiZXvuvWdsDyGnwC4AlLoE4IXiRc5FPEqeiR0yAsVlkjHBd-M-6snacEAOvX9ljBcpyH1yIJSQwFk-Ip-P1qw6dElldcCaLnVl2qA_0CRohtD2C-oD9sHTxjoaXpAGhzp0sURt861ZH3O9Du07Uu0Cuta-x-oQI60Pg9H-is5sv0ii1FGHfjBrnLPdN-9mNr-ejiNpqFfHZK_RxuPJdj0i89ubp8l9Mnu4m07Gs6QSkoUEgGGqVF5IBkLLtFAgmSjqlBeccQAhMGfyudIV8Bx4WmSNQpZmdSN4WqeZOCLnG-7S2bcBfSi71ldojO4xXrzkOc9FJmOzaIWNtXLWe4dNuXRtp92qBFaup1D-mULMnG3xw3OH9W_i59uj4WJj8HqB5asdXB-f-w_xC8Whj-U</recordid><startdate>20240901</startdate><enddate>20240901</enddate><creator>Katsanos, Konstantinos</creator><creator>Ho, Pei</creator><creator>Tang, Tjun Yip</creator><creator>Vlachou, Elina</creator><creator>Yap, Charyl Jia Qi</creator><creator>Kitrou, Panagiotis M</creator><creator>Karnabatidis, Dimitrios</creator><general>SAGE Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6312-1836</orcidid><orcidid>https://orcid.org/0000-0003-4560-2374</orcidid><orcidid>https://orcid.org/0000-0002-8606-0842</orcidid></search><sort><creationdate>20240901</creationdate><title>Polymer-coated paclitaxel-eluting stents for the treatment of stenosed native arteriovenous fistulas: Long-term results from the ELUDIA study</title><author>Katsanos, Konstantinos ; Ho, Pei ; Tang, Tjun Yip ; Vlachou, Elina ; Yap, Charyl Jia Qi ; Kitrou, Panagiotis M ; Karnabatidis, Dimitrios</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c340t-110e577894013a459714039d5292021133e804bcac12812596f7e056df325d563</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Aged</topic><topic>Angioplasty, Balloon - adverse effects</topic><topic>Angioplasty, Balloon - instrumentation</topic><topic>Arteriovenous Shunt, Surgical - adverse effects</topic><topic>Cardiovascular Agents - administration &amp; dosage</topic><topic>Coated Materials, Biocompatible</topic><topic>Drug-Eluting Stents</topic><topic>Female</topic><topic>Graft Occlusion, Vascular - diagnostic imaging</topic><topic>Graft Occlusion, Vascular - etiology</topic><topic>Graft Occlusion, Vascular - physiopathology</topic><topic>Graft Occlusion, Vascular - therapy</topic><topic>Greece</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Paclitaxel - administration &amp; dosage</topic><topic>Prosthesis Design</topic><topic>Recurrence</topic><topic>Renal Dialysis</topic><topic>Risk Factors</topic><topic>Tertiary Care Centers</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Upper Extremity - blood supply</topic><topic>Vascular Patency</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Katsanos, Konstantinos</creatorcontrib><creatorcontrib>Ho, Pei</creatorcontrib><creatorcontrib>Tang, Tjun Yip</creatorcontrib><creatorcontrib>Vlachou, Elina</creatorcontrib><creatorcontrib>Yap, Charyl Jia Qi</creatorcontrib><creatorcontrib>Kitrou, Panagiotis M</creatorcontrib><creatorcontrib>Karnabatidis, Dimitrios</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The journal of vascular access</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Katsanos, Konstantinos</au><au>Ho, Pei</au><au>Tang, Tjun Yip</au><au>Vlachou, Elina</au><au>Yap, Charyl Jia Qi</au><au>Kitrou, Panagiotis M</au><au>Karnabatidis, Dimitrios</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Polymer-coated paclitaxel-eluting stents for the treatment of stenosed native arteriovenous fistulas: Long-term results from the ELUDIA study</atitle><jtitle>The journal of vascular access</jtitle><addtitle>J Vasc Access</addtitle><date>2024-09-01</date><risdate>2024</risdate><volume>25</volume><issue>5</issue><spage>1593</spage><epage>1600</epage><pages>1593-1600</pages><issn>1129-7298</issn><issn>1724-6032</issn><eissn>1724-6032</eissn><abstract>Background: Percutaneous transluminal angioplasty is the preferred treatment of stenosed failing arteriovenous fistulas (AVF) but is hampered by increasing rates of vascular restenosis because of development of myointimal hyperplasia. Methods: This multicenter observational study of polymer-coated low-dose paclitaxel-eluting stents (ELUvia stents by Boston Scientific) in stenosed AVF undergoing hemoDIAlysis (ELUDIA) was jointly conducted in three tertiary hospitals from Greece and Singapore. Failure of AVF was defined according to K-DOQI criteria and significant fistula stenosis (&gt;50%DS by visual estimate) was determined with subtraction angiography. Patients were considered for ELUVIA stent insertion based on significant elastic recoil following balloon angioplasty for the treatment of a single vascular stenosis within a native AVF. The primary outcome measure was sustained long-term patency of the treated lesion/fistula circuit defined as successful stent placement with resumption of uninterrupted hemodialysis and without significant vascular restenosis (50%DS threshold) or other secondary interventions during follow-up. Results: Some 23 patients received the ELUVIA paclitaxel-eluting stent (eight radiocephalic, 12 brachiocephalic, and three transposed brachiobasilic native AVFs). Mean AVF age at the time of failure was 33.9 ± 20.4 months. Treated lesions included 12 stenoses at the juxta-anastomotic segment, nine at the outflow veins, and two cephalic arch lesions with a mean diameter stenosis of 86 ± 8%. Median stent diameter and length used were 7 mm and 40 mm, respectively. After a median follow-up period of 20 months, some 18 stents out of 23 cases remained patent (cumulative rate 78.3%) without any clinical or imaging evidence of recurrent stenosis. Estimated primary patency of the ELUVIA stents was 80.6% and of the corresponding fistula circuit 65.1% at 2 years by Kaplan-Meier methods. Conclusions: This observational study has shown promising long-term results of polymer-coated paclitaxel-eluting stents for the treatment of failing arteriovenous fistulas. Large-scale controlled studies are necessary.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>37341208</pmid><doi>10.1177/11297298231174263</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-6312-1836</orcidid><orcidid>https://orcid.org/0000-0003-4560-2374</orcidid><orcidid>https://orcid.org/0000-0002-8606-0842</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1129-7298
ispartof The journal of vascular access, 2024-09, Vol.25 (5), p.1593-1600
issn 1129-7298
1724-6032
1724-6032
language eng
recordid cdi_proquest_miscellaneous_2828364340
source Access via SAGE; MEDLINE
subjects Aged
Angioplasty, Balloon - adverse effects
Angioplasty, Balloon - instrumentation
Arteriovenous Shunt, Surgical - adverse effects
Cardiovascular Agents - administration & dosage
Coated Materials, Biocompatible
Drug-Eluting Stents
Female
Graft Occlusion, Vascular - diagnostic imaging
Graft Occlusion, Vascular - etiology
Graft Occlusion, Vascular - physiopathology
Graft Occlusion, Vascular - therapy
Greece
Humans
Male
Middle Aged
Paclitaxel - administration & dosage
Prosthesis Design
Recurrence
Renal Dialysis
Risk Factors
Tertiary Care Centers
Time Factors
Treatment Outcome
Upper Extremity - blood supply
Vascular Patency
title Polymer-coated paclitaxel-eluting stents for the treatment of stenosed native arteriovenous fistulas: Long-term results from the ELUDIA study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-11-30T12%3A42%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Polymer-coated%20paclitaxel-eluting%20stents%20for%20the%20treatment%20of%20stenosed%20native%20arteriovenous%20fistulas:%20Long-term%20results%20from%20the%20ELUDIA%20study&rft.jtitle=The%20journal%20of%20vascular%20access&rft.au=Katsanos,%20Konstantinos&rft.date=2024-09-01&rft.volume=25&rft.issue=5&rft.spage=1593&rft.epage=1600&rft.pages=1593-1600&rft.issn=1129-7298&rft.eissn=1724-6032&rft_id=info:doi/10.1177/11297298231174263&rft_dat=%3Cproquest_cross%3E2828364340%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2828364340&rft_id=info:pmid/37341208&rft_sage_id=10.1177_11297298231174263&rfr_iscdi=true